The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

Abstract

HER2-positive breast cancer is an aggressive disease. As a result of the development of specific HER2-targeted therapies, such as trastuzumab, more than 20 years ago, the prognosis of these patients has improved. Metastatic HER2-positive breast cancer patients are achieving better survival rates upon treatment with anti-HER2 therapies than patients with HER2-negative disease. Double HER2 blockade with trastuzumab and pertuzumab combined with a taxane achieved an unprecedented survival of over 57 months in first-line patients. Trastuzumab emtansine, the first antibody-drug conjugate approved for patients in second-line treatment was a potent cytotoxic agent bound to trastuzumab and is currently a standard therapeutic strategy. Despite the progress in treatment development, most patients develop resistance and eventually relapse. Advances in the design of antibody-drug conjugates have led to the development of new generation drugs with enhanced properties, such as trastuzumab deruxtecan and trastuzumab duocarmazine, which are significantly changing the paradigm in the treatment of HER2-positive metastatic breast cancer.

Keywords

Breast cancer / HER2-positive / ADCs / New drugs / Mechanisms of resistance

References

[1] Haque R,Inzhakova G.Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.Cancer Epidemiol Biomarkers Prev2012;21:1848-55 PMCID:PMC3467337

[2] Slamon DJ,Shak S.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001;344:783-92

[3] Perez EA,Suman VJ.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.J Clin Oncol2014;32:3744-52 PMCID:PMC4226805

[4] Valabrega G,Aglietta M.Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.Ann Oncol2007;18:977-84

[5] Mukohara T.Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.Cancer Sci2011;102:1-8

[6] Metzger-Filho O,Krop I.Pertuzumab: optimizing HER2 blockade.Clin Cancer Res2013;19:5552-6

[7] Swain SM,Kim S.Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.Lancet Oncol2020;21:519-30

[8] Diéras V,Verma S.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.Lancet Oncol2017;18:732-42 PMCID:PMC5531181

[9] Verma S,Gianni L.EMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med2012;367:1783-91 PMCID:PMC5125250

[10] Perez EA,Eiermann W.Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE.Cancer2019;125:3974-84

[11] Hurvitz SA,Jung KH.Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study.J Clin Oncol2019;37:2206-16 PMCID:PMC6774816

[12] von Minckwitz G, Huang CS, Mano MS, et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med2019;380:617-28

[13] Hunter FW,Lipert B.Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.Br J Cancer2020;122:603-12 PMCID:PMC7054312

[14] Trail PA,Lowinger TB.Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design.Pharmacol Ther2018;181:126-42

[15] Erickson HK,Widdison WC.Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.Cancer Res2006;66:4426-33

[16] Mittendorf EA,Scaltriti M.Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.Clin Cancer Res2009;15:7381-8 PMCID:PMC2788123

[17] Sakai H,Iwasa T.HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.Breast Cancer2018;25:605-13 PMCID:PMC6132843

[18] Gebhart G,Wimana Z.Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.Ann Oncol2016;27:619-24

[19] Filho OM,Stein S.Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.Cancer Discov2021;11:2474-87 PMCID:PMC8598376

[20] Kovtun YV,Mayo MF.Antibody-maytansinoid conjugates designed to bypass multidrug resistance.Cancer Res2010;70:2528-37

[21] Sabbaghi M,Guardia C.Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.Clin Cancer Res2017;23:7006-19

[22] Emens LA,Beresford M.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol2020;21:1283-95

[23] ClinicalTrials.gov. A study evaluating the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for participants with HER2-positive breast cancer at high risk of recurrence following preoperative therapy (Astefania). Available from: https://clinicaltrials.gov/ct2/show/NCT04873362 [Last accessed on 29 Dec 2022]

[24] ClinicalTrials.gov. A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for patients with advanced or metastatic HER2+ breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03975647 [Last accessed on 29 Dec 2022]

[25] Modi S,Yamashita T.DESTINY-Breast04 Trial InvestigatorsTrastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N Engl J Med2022;387:9-20

[26] Ferraro E,Modi S.Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.Breast Cancer Res2021;23:84 PMCID:PMC8356386

[27] Rinnerthaler G,Greil R.HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer.Int J Mol Sci2019;20:1115 PMCID:PMC6429068

[28] Li L,Liu B.Antibody-drug conjugates in HER2-positive breast cancer.Chin Med J2021;135:261-7 PMCID:PMC8812658

[29] Ogitani Y,Hagihara K.DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1.Clin Cancer Res2016;22:5097-108

[30] Tamura K,Takahashi S.Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.Lancet Oncol2019;20:816-26

[31] Modi S,Yamashita T.DESTINY-Breast01 InvestigatorsTrastuzumab deruxtecan in previously treated HER2-positive breast cancer.N Engl J Med2020;382:610-21 PMCID:PMC7458671

[32] Modi S,Yamashita T.Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium; 2020.

[33] Cortés J,Chung WP.DESTINY-Breast03 Trial InvestigatorsTrastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N Engl J Med2022;386:1143-54

[34] Gennari A,Barrios CH.ESMO Guidelines CommitteeElectronic address: [e-mail]. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.Ann Oncol2021;32:1475-95

[35] ClinicalTrials.gov. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). Available from: https://clinicaltrials.gov/ct2/show/NCT04784715 [Last accessed on 29 Dec 2022]

[36] ClinicalTrials.gov. A study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive participants with residual invasive breast cancer following neoadjuvant therapy (DESTINY-Breast05). Available from: https://clinicaltrials.gov/ct2/show/NCT04622319 [Last accessed on 29 Dec 2022]

[37] ClinicalTrials.gov. Trastuzumab deruxtecan (T-DXd) alone or in sequence with THP, versus standard treatment (ddAC-THP), in HER2-positive early breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT05113251 [Last accessed on 29 Dec 2022]

[38] Elgersma RC,Huijbregts T.Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985.Mol Pharm2015;12:1813-35

[39] van der Lee MM,Ubink R.The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers.Mol Cancer Ther2015;14:692-703

[40] Banerji U,Saura C.Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol2019;20:1124-35

[41] Manich CS,Aftimos PG.LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer.Ann Oncol2021;32:S1288

[42] Skidmore L,Knudsen NA.ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers.Mol Cancer Ther2020;19:1833-43

[43] Zhang J,Shen W,Gu Y.Safety and anti-tumoractivity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01 trial results. San Antonio Breast Cancer Symposium; 2021.

[44] ClinicalTrials.gov. ARX788 in HER2-positive, metastatic breast cancer subjects (ACE-Breast-03). Available from: https://clinicaltrials.gov/ct2/show/study/NCT04829604 [Last accessed on 29 Dec 2022]

[45] Wang J,Zhang Q.RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies.J Clin Oncol2021;39:1022-1022

[46] ClinicalTrials.gov. A study of RC48-ADC administered intravenously to patients with HER2-positive metastatic breast cancer with or without liver metastases. Available from: https://clinicaltrials.gov/ct2/show/NCT03500380 [Last accessed on 29 Dec 2022]

[47] Saura C,Feng YH.NALA InvestigatorsNeratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial.J Clin Oncol2020;38:3138-49 PMCID:PMC7499616

[48] Xu B,Ma F.Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Oncol2021;22:351-60

[49] Hamblett K,Davies R.Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers.Cancer Res2019;79:P6-17

[50] ClinicalTrials.gov. A dose finding study of ZW49 in patients with HER2-positive cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT03821233 [Last accessed on 29 Dec 2022]

[51] Jhaveri K,Dotan E.460MO preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers.Ann Oncol2022;33:S197-S224

[52] Pegram MD,Tan AR.First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer.Mol Cancer Ther2021;20:1442-53

[53] de Dieras V, Lusque A. Trastuzumab deruxtecan for advanced breast cancer patients, regardless of HER2 status: a phase II study with biomarkers analysis (DAISY). San Antonio Breast Cancer Symposium; 2021.

[54] Mosele MF,Dieras V.LBA1 unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial.Ann Oncol2022;33:S123-S147

[55] Mosele MF,Dieras VC.LBA72 unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial.Ann Oncol2022;33:S808-S869

[56] Montemurro F,Barrios CH.Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(☆).Ann Oncol2020;31:1350-8

[57] Pérez-García JM,Cortez P.Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial.Neuro Oncol2022:noac144

[58] Bartsch R,Furtner J.Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.Nat Med2022;28:1840-7 PMCID:PMC9499862

[59] ClinicalTrials.gov. A study of T-DXd in participants with or without brain metastasis who have previously treated advanced or metastatic HER2 positive breast cancer (DESTINY-B12). Available from: https://clinicaltrials.gov/ct2/show/NCT04739761 [Last accessed on 29 Dec 2022]

[60] ClinicalTrials.gov. Evaluation of safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular toxicity in cancer patients treated with SYD985. Available from: https://clinicaltrials.gov/ct2/show/NCT04983238 [Last accessed on 29 Dec 2022]